Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

NewsGuard 100/100 Score

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases. The randomized, double-blind, placebo-controlled Phase III trial is designed to determine the effects of Stivarga as adjuvant treatment following surgical removal of liver metastases.

"Patients with more advanced colorectal cancer often develop liver metastases – meaning the disease has spread to the liver," said Joseph Germino, Vice President of Medical Affairs, Oncology, Bayer HealthCare. "The COAST trial will investigate treatment with Stivarga in these patients following surgery to remove liver tumors and completion of chemotherapy."

Stivarga is approved by the U.S. Food and Drug Administration (FDA) to treat two different tumor types. In September 2012, Stivarga was first approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. In February 2013, the FDA also approved Stivarga to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.2

Source: Bayer HealthCare Pharmaceuticals Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research unlocks the role of macrophages in cancer relapse